Treatment satisfaction in type 2 diabetes patients taking empagliflozin compared with patients taking glimepiride

about

Efficacy and safety of empagliflozin in type 2 diabetes mellitus: a meta-analysis of randomized controlled trials.Dapagliflozin improves treatment satisfaction in overweight patients with type 2 diabetes mellitus: a patient reported outcome study (PRO study).

P2860

Q39007677-C1BB0BE2-3663-4AED-8251-ABFC2221CC5F Q51744128-6EEAE859-BF66-4F5E-B852-C6655E15241E

P2860

Treatment satisfaction in type 2 diabetes patients taking empagliflozin compared with patients taking glimepiride

Item

http://www.wikidata.org/entity/Q36823710

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Treatment satisfaction in type ...... th patients taking glimepiride

@en

type

Item

label

Treatment satisfaction in type ...... th patients taking glimepiride

@en

prefLabel

Treatment satisfaction in type ...... th patients taking glimepiride

@en

P1476

Treatment satisfaction in type ...... th patients taking glimepiride

@en

P2093

Costel Chirila

http://www.w3.org/2001/XMLSchema#string

Dagmar Kaschinski

http://www.w3.org/2001/XMLSchema#string

Egon Pfarr

http://www.w3.org/2001/XMLSchema#string

Eric Davenport

http://www.w3.org/2001/XMLSchema#string

Qingyao Zheng

http://www.w3.org/2001/XMLSchema#string

Roberto Palencia

http://www.w3.org/2001/XMLSchema#string

Thomas Hach

http://www.w3.org/2001/XMLSchema#string

P2860

Renal Na(+)-glucose cotransporters

The sodium/glucose cotransport family SLC5

Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes

Feedback on the FDA's February 2006 draft guidance on Patient Reported Outcome (PRO) measures from a developer of PRO measures.

The Diabetes Treatment Satisfaction Questionnaire change version (DTSQc) evaluated in insulin glargine trials shows greater responsiveness to improvements than the original DTSQ.

Improving treatment satisfaction and other patient-reported outcomes in people with type 2 diabetes: the role of once-daily insulin glargine.

How does treatment satisfaction work?: Modeling determinants of treatment satisfaction and preference.

Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial

Current antihyperglycemic treatment guidelines and algorithms for patients with type 2 diabetes mellitus.

Measures of psychological well-being and treatment satisfaction developed from the responses of people with tablet-treated diabetes.

P2888

s11136-015-1140-2

P304

1199-1207

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S11136-015-1140-2

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-09-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

282362139

http://www.w3.org/2001/XMLSchema#string

P698

26424170

http://www.w3.org/2001/XMLSchema#string

P932

4840220

http://www.w3.org/2001/XMLSchema#string

Treatment satisfaction in type 2 diabetes patients taking empagliflozin compared with patients taking glimepiride

about

P2860

P2860

Treatment satisfaction in type 2 diabetes patients taking empagliflozin compared with patients taking glimepiride

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P5875

P698

P932

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P5875

P698

P932